NeuroGene completed dosing in the NGN-401 pivotal study and expects data in the second half of 27. It had about $360 million in cash and equivalents at quarter-end, funding operations into the first quarter of 29.
NGNE · Neurogene Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 70%
- Last earnings
- Aug 11, 2025
- Latest filing
- 10-Q · Nov 9
- Price history
- Jan 2020 to Nov 2026
Latest documents
Neurogene Inc. completed dosing 25 participants in the Embolden registrational trial for NGN-401, expects topline results in the second half of 2027, and expects cash, cash equivalents and investments to fund operations into the first quarter of 2029.
Neurogene reported $359.7 million in cash and investments as of September 30, 2026, funding operations into first quarter 2029. NGN-401 Embolden topline data are expected in 2H 2027, with PPQ runs expected to complete by year-end 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Average milestones per participant | 1.9 | at 6 months | — |
| Average milestones per participant at 12 months | 3.7 | 12 months | — |
| Average milestones per participant at 6 months | 0.9 | 6 months | — |
| Embolden Composite responder rate (CGI-I ≤3 + ≥1 milestone) | 80% | as of data cutoff date of June 16, 2026 | — |
| Embolden milestones gained across 10 Phase 1/2 participants | 21 | as of data cutoff date of June 16, 2026 | — |
| Mean RSGMS total-score gain | 5.2 | Post treatment (N=10) | — |
| Mean RSHFS total-score gain per hand | 1.8 | Post treatment (N=10; 1-2.5 years) | — |
| Median time to first response | 2 | median time observed post treatment | — |
| Participants gained ≥1 developmental milestone at ≥12 months | 100% | at ≥12 months | — |
| Phase 1/2 participants gaining ≥1 developmental milestone and improving on CGI-I | 100% | at ≥12 months | — |
| Phase 1/2 participants gaining ≥2 developmental milestones | 7 | data cutoff date of June 16, 2026 | — |
| Response rate (Phase 1/2 responders at 12 months) | 80% | Phase 1/2 at 12 months | — |
| Total developmental milestones gained | 47 | as of data cutoff date of June 16, 2026 | — |
| Total NGN-401 participants dosed in Embolden | 25 | as of data cutoff date of June 16, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NGNE
this stock
Neurogene Inc.
|
$458.53M | +7.5% | -100.0% | — | 27.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 11, 2026
- This year
- 19
NeuroGene completed dosing in the NGN-401 pivotal study and expects data in the second half of 27. It had about $360 million in cash and equivalents at quarter-end, funding operations into the first quarter of 29.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NGNE | -7.4% | -5.9% | -15.3% | -19.6% | +7.5% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +1.1% | +3.3% | -6.1% | -10.9% | +6.4% |